The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing ...

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven ...

On Tuesday, 11 March 2025, Catalyst Pharmaceuticals (NASDAQ: CPRX) presented at the Barclays 27th Annual Global Healthcare Conference. The company highlighted its strategic focus on organic growth ...

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Baird raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $32 from $28 and keeps an Outperform rating on the shares. The firm ...

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday. Several other research ...

CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...